NicOx Buys Back Glaucoma Drug Rights From Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.